Subtype
Bladder Urothelial Carcinoma
CI-CAN-00004632Explore in graph →
60 active trials5 evidence items
- NCIt
- C39851
- OncoTree
- BLCA
- DOID
- 4006
- UMLS CUI
- C0279680
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004632Explore in graph →
Clinical trials
138 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (21)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07234968 | Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy | recruiting | N/A | 70 | Thomas Jefferson UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06764095 | Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial | recruiting | Phase 4 | 75 | Mayo ClinicOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06818136 | Bladder EpiCheck European Haematuria Study | recruiting | — | 800 | Nucleix Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05962541 | Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)(CUT-less) | recruiting | Phase 4 | 327 | University of Roma La SapienzaOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07279597 | A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer | not yet recruiting | Phase 2 | 45 | Tongji HospitalOTHER | 0 | Dec 19, 2025 | clinicaltrials |
| NCT06263153 | Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy | recruiting | Phase 2 | 24 | Yuanquan YangOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03582475 | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | active not recruiting | Phase 1 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT06396533 | Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)(INSITE) | recruiting | — | 92 | Fox Chase Cancer CenterOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06727214 | Survival Benefits of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer(AssiutU) | not yet recruiting | — | 87 | Sara Mahmoud Ahmed MahmoudOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT04574960 | Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)(NAUTICAL) | recruiting | Phase 3 | 14 | University Health Network, TorontoOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07064863 | A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.(BCG-TIME) | not yet recruiting | Phase 1 / Phase 2 | 31 | Queen's UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06257017 | Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma | recruiting | Phase 2 | 20 | Yung NAOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06766266 | Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment | recruiting | Phase 1 | 18 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT02202772 | Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder(CGC) | active not recruiting | Phase 1 / Phase 2 | 51 | Guarionex J. DecastroOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04167631 | Can VI-RADS/ADC Accurately Stage Bladder Cancer?? | active not recruiting | N/A | 150 | Mansoura UniversityOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06528483 | Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer(preSAVE) | not yet recruiting | Phase 2 | 63 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06170177 | Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy | recruiting | — | 4,000 | IRCCS San RaffaeleOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT06167356 | Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK. | recruiting | — | 20,000 | IRCCS San RaffaeleOTHER | 1 | Dec 12, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Feb 17, 2026source: clinicaltrials